Novartis will need to boost Xiidra sales to justify the hefty price it has paid, but the Swiss company has form.
A poor quarter is followed by an acquisition, but is it big enough?
Acelity falls to 3M, but the conglomerate has taken on a great deal of debt and could see its credit rating fall.
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
Perhaps sensing trouble ahead Kiadis diversifies beyond ATIR101 by buying Cytosen, but it is a scientific appointment that will cause real excitement.
The RNAi specialist gets an $800m cash injection under a central nervous system tie-up with Regeneron.
UK group bets billions on an Her2 project slated for late-line patients and those with lower expression of the target protein.
Probiodrug grabs $15m, but it will need more to fund phase IIb development of its Alzheimer’s candidate, PQ912.
The UK ortho and woundcare group might yet pounce on Nuvasive.